Fewer Complications at 18 Months Seen With Post-COVID-19 Vaccination Myocarditis
By Lori Solomon HealthDay Reporter
THURSDAY, Aug. 29, 2024 -- Patients with post-COVID-19 mRNA vaccination myocarditis show a lower frequency of cardiovascular complications than those with conventional myocarditis or post-COVID-19 myocarditis at 18 months, according to a study published online Aug. 26 in the Journal of the American Medical Association.
Laura Semenzato, from the French National Agency for the Safety of Medicines and Health Products and French National Health Insurance, and colleagues examined the prognosis and management of post-COVID-19 mRNA vaccination myocarditis compared to other types of myocarditis during 18 months of follow-up. The analysis included 4,635 individuals who were hospitalized for myocarditis, including 558 with postvaccine myocarditis, 298 with post-COVID-19 myocarditis, and 3,779 with conventional myocarditis.
The researchers found that patients with postvaccine myocarditis were younger than those with post-COVID-19 and conventional myocarditis (mean age, 25.9, 31.0, and 28.3 years, respectively) and were more frequently men (84, 67, and 79 percent, respectively). There was a lower standardized incidence of the composite clinical outcome (hospital readmission for myopericarditis, other cardiovascular events, and all-cause death) for patients with postvaccine myocarditis than those with conventional myocarditis (weighted hazard ratio, 0.55; 95 percent confidence interval, 0.36 to 0.86). Individuals with post-COVID-19 myocarditis had similar outcomes to conventional myocarditis (weighted hazard ratio, 1.04; 95 percent confidence interval, 0.70 to 1.52). Postvaccine myocarditis and post-COVID-19 myocarditis showed a similar trend for frequency of medical procedures and drugs prescribed posthospital discharge to that of patients with conventional myocarditis.
"Affected patients, mainly healthy young men, may require medical disease management for up to several months after hospital discharge," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Further Support and Information on COVID-19
Read this next
Seniors With Certain Cardiovascular Diseases Saw Life's Essential 8 Scores Decline 2013 to 2018
WEDNESDAY, Aug. 20, 2025 -- From 2013 to 2018, older adults with heart failure, stroke, and hypertension experienced significant declines in Life's Essential 8 (LE8) scores...
Tdap, MenACWY Coverage Increased in Teens From 2023 to 2024
TUESDAY, Aug. 19, 2025 -- From 2023 to 2024, coverage with one or more doses of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) and the...
Two Doses of Zoster Vaccine Reduce Risk for Herpes Zoster Ophthalmicus
TUESDAY, Aug. 19, 2025 -- Two doses of recombinant zoster vaccine (RZV) are associated with a reduced risk for herpes zoster ophthalmicus (HZO), acute myocardial infarction, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.